Följ
Yevgeniy Samyshkin
Yevgeniy Samyshkin
Director, Value Evidence Analytics, GSK
Verifierad e-postadress på gsk.com - Startsida
Titel
Citeras av
Citeras av
År
Cost-effectiveness of stroke unit care followed by early supported discharge
O Saka, V Serra, Y Samyshkin, A McGuire, CCDA Wolfe
Stroke 40 (1), 24-29, 2009
1572009
Estimating the impact of better management of glycaemic control in adults with type 1 and type 2 diabetes on the number of clinical complications and the associated financial …
M Baxter, R Hudson, J Mahon, C Bartlett, Y Samyshkin, D Alexiou, N Hex
Diabetic Medicine 33 (11), 1575-1581, 2016
1322016
A framework and toolkit for capturing the communicable disease programmes within health systems: tuberculosis control as an illustrative example
RA Atun, N Lennox-Chhugani, F Drobniewski, YA Samyshkin, RJ Coker
The European Journal of Public Health 14 (3), 267-273, 2004
1102004
Barriers to sustainable tuberculosis control in the Russian Federation health system
RA Atun, YA Samyshkin, F Drobniewski, NM Skuratova, G Gusarova, ...
Bulletin of the World Health Organization 83 (3), 217-223c, 2005
862005
Tuberculosis control in Samara Oblast, Russia: institutional and regulatory environment
RJ Coker, B Dimitrova, F Drobniewski, Y Samyshkin, Y Balabanova, ...
The international journal of tuberculosis and lung disease 7 (10), 920-932, 2003
742003
Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis
N Hertel, RW Kotchie, Y Samyshkin, M Radford, S Humphreys, ...
International journal of chronic obstructive pulmonary disease, 183-199, 2012
692012
Seasonal variation and hospital utilization for tuberculosis in Russia: hospitals as social care institutions
RA Atun, YA Samyshkin, F Drobniewski, SI Kuznetsov, IM Fedorin, ...
The European Journal of Public Health 15 (4), 350-354, 2005
682005
Mental health reform in the Russian Federation: an integrated approach to achieve social inclusion and recovery
R Jenkins, S Lancashire, D McDaid, Y Samyshkin, S Green, J Watkins, ...
Bulletin of the World health Organization 85 (11), 858-866, 2007
662007
Health-systems efficiency in the Russian Federation: tuberculosis control
K Floyd, R Hutubessy, Y Samyshkin, A Korobitsyn, I Fedorin, ...
Bulletin of the World Health Organization 84 (1), 43-51, 2006
582006
Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios
M Hoogendoorn, TL Feenstra, Y Asukai, S Borg, RN Hansen, SA Jansson, ...
Value in health 17 (5), 525-536, 2014
502014
Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US
Y Samyshkin, AL Guillermin, JH Best, SC Brunell, A Lloyd
Journal of medical economics 15 (sup2), 6-13, 2012
442012
Health system factors impacting on delivery of mental health services in Russia: multi-methods study
D McDaid, YA Samyshkin, R Jenkins, A Potasheva, A Nikiforov, RA Atun
Health Policy 79 (2-3), 144-152, 2006
432006
Utilising artificial intelligence to determine patients at risk of a rare disease: idiopathic pulmonary arterial hypertension
DG Kiely, O Doyle, E Drage, H Jenner, V Salvatelli, FA Daniels, J Rigg, ...
Pulmonary circulation 9 (4), 2045894019890549, 2019
412019
Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes …
WC Lee, Y Samyshkin, J Langer, JL Palmer
Journal of medical economics 15 (sup2), 28-37, 2012
392012
Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom
Y Samyshkin, RW Kotchie, AC Mörk, AH Briggs, ED Bateman
The European Journal of Health Economics 15, 69-82, 2014
382014
Costs and outcomes of tuberculosis control in the Russian Federation: retrospective cohort analysis
RA Atun, Y Samyshkin, F Drobniewski, Y Balabanova, IM Fedorin, J Lord, ...
Health Policy and Planning 21 (5), 353-364, 2006
332006
Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States
AL Guillermin, A Lloyd, JH Best, MB DeYoung, Y Samyshkin, JA Gaebler
Journal of medical economics 15 (4), 654-663, 2012
322012
Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland
Y Samyshkin, M Schlunegger, S Haefliger, S Ledderhose, M Radford
International Journal of Chronic Obstructive Pulmonary Disease, 79-87, 2013
302013
Social factors influencing hospital utilisation by tuberculosis patients in the Russian Federation: analysis of routinely collected data
RA Atun, YA Samyshkin, F Drobniewski, SI Kuznetsov, IM Fedorin, ...
The international journal of tuberculosis and lung disease 9 (10), 1140-1146, 2005
302005
External validation of health economic decision models for chronic obstructive pulmonary disease (COPD): report of the third COPD modeling meeting
M Hoogendoorn, TL Feenstra, Y Asukai, AH Briggs, RN Hansen, R Leidl, ...
Value in Health 20 (3), 397-403, 2017
272017
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20